Recurrent Melanoma Active Not Recruiting Phase 2 Trials for Dabrafenib (DB08912)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02196181Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryTreatment